$1.45
6.45% yesterday
Nasdaq, Jun 17, 10:01 pm CET
ISIN
US3741631036
Symbol
GERN
Sector
Industry

Geron Corporation Stock price

$1.45
+0.06 4.32% 1M
-2.48 63.10% 6M
-2.09 59.04% YTD
-3.22 68.95% 1Y
-0.30 17.14% 5Y
-2.43 62.63% 10Y
-5.74 79.83% 20Y
Nasdaq, Closing price Tue, Jun 17 2025
-0.10 6.45%
ISIN
US3741631036
Symbol
GERN
Sector
Industry

Key metrics

Market capitalization $987.22m
Enterprise Value $709.07m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.10
P/S ratio (TTM) P/S ratio 8.49
P/B ratio (TTM) P/B ratio 3.68
Revenue growth (TTM) Revenue growth 22,263.46%
Revenue (TTM) Revenue $116.29m
EBIT (operating result TTM) EBIT $-136.01m
Free Cash Flow (TTM) Free Cash Flow $-204.34m
Cash position $396.88m
EPS (TTM) EPS $-0.21
P/E forward negative
P/S forward 4.97
EV/Sales forward 3.57
Short interest 10.60%
Show more

Is Geron Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,866 stocks worldwide.

Geron Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Geron Corporation forecast:

6x Buy
67%
3x Hold
33%

Analyst Opinions

9 Analysts have issued a Geron Corporation forecast:

Buy
67%
Hold
33%

Financial data from Geron Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
116 116
22,263% 22,263%
100%
- Direct Costs 2.46 2.46
-
2%
114 114
-
98%
- Selling and Administrative Expenses 159 159
90% 90%
136%
- Research and Development Expense 89 89
30% 30%
77%
-135 -135
36% 36%
-116%
- Depreciation and Amortization 1.42 1.42
216% 216%
1%
EBIT (Operating Income) EBIT -136 -136
35% 35%
-117%
Net Profit -139 -139
31% 31%
-120%

In millions USD.

Don't miss a Thing! We will send you all news about Geron Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Geron Corporation Stock News

Positive
Seeking Alpha
14 days ago
This is a follow-up coverage of the Geron Corp., a small biotech company that markets first-in-class drug Imetelstat for the treatment of myelodysplastic syndrome (MDS). The first three full-quarter sales of the imetelstat did not meet stock market expectations; consequently, share price went down by 70%. Conservative analysis of the disease, epidemiology, drug properties, and competition sugge...
Neutral
Business Wire
20 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)---- $GERN--Geron announces presentations on RYTELO® (imetelstat) at 2025 ASCO Annual Meeting and EHA 2025 Congress.
Neutral
Business Wire
29 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 411,000 shares of its common stock, consisting of stock options to purchase an aggregate of 274,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate of 137,000 shares o...
More Geron Corporation News

Company Profile

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.

Head office United States
CEO Dawn Bir
Employees 229
Founded 1990
Website www.geron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today